Inhibition of the Cyclin K-CDK12 Complex Induces DNA Damage and Increases the Effect of Androgen Deprivation Therapy in Prostate Cancer

Scientists investigated the suitability of the Cyclin K-CDK12 complex as a novel therapeutic approach in prostate cancer using the new covalent CDK12/13 inhibitor THZ531.